Hefei Tiangang immunopharmaceutical Co., Ltd., a tumor immunotherapy enterprise, completed a round of pre-A financing of hundreds of millions of yuan

Pure Global: The International Engine of Medical Technology Globalization

As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline

EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.

Insilico Medicine submitted a listing application to the Hong Kong Stock Exchange

On March 27, Insilico Medicine, an AI drug research and development company, once again submitted its listing application to the Hong Kong Stock Exchange.